Shots:

• Beam to get an exclusive right to develop prime editing technology to treat sickle cell disease and for single-base transition mutations both of which Beam is pursuing with its base editing technology
• The collaboration allows both companies to advance their technology in distinct space with a Beam to focus on the kinds of edits like the base editing technology. Beam plans to evaluate prime editing technology for potential use in future programs
• Beam will provide interim leadership to Prime Medicine for the first year of the collaboration and will get the right to designate a member on Prime Medicine’s board. Additionally- both the companies will grant each other non-exclusive licenses to CRISPR technology and delivery technology- enabling the development of prime editing products

Click here to­ read full press release/ article | Ref: Business Wire | Image: Beam Therapeutics